Celladon Will Become Rare Disease-Focused Eiger
This article was originally published in Scrip
Celladon Corp. will be acquired in a reverse merger with Eiger BioPharmaceuticals Inc., which means Celladon will not have to liquidate its assets to return cash to shareholders following discontinuation of development for the genetically-targeted enzyme replacement therapy Mydicar for heart failure.
You may also be interested in...
Finding no improvement with ubenimex in PAH, Eiger ends development but continues with the drug in lymphedema, plus hepatitis D and post-bariatric hypoglycemia candidates.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.